The time is now
Psychedelic compounds can lead to major breakthroughs in the treatment of depression, anxiety, and addiction, as recognized by the FDA and the scientific community. We work with science-led teams advancing and redefining the standard of patient care.
Clinical results are impressive
Liberalisation is expanding
Regulation is on the way
Our investments
Average ticket size
£150k - £1m
Target stage
Pre-Seed to Series A
Target markets
Global, with a European tilt
Investment categories
Compounds, clinics and care delivery, digital therapeutics and platforms
Our ecosystem
Specialist
Largest European VC fund with a reputation for discipline and diligence
Network
We work closely with leaders in this sector, with relationships going back 15 years
Ecosystem
We're building an ecosystem. We provide more than just capital, working with founders from scratch to success
Our portfolio
Our partners
We are actively involved in shaping policy, working closely with our partners at Drug Science and the International Therapeutic Psilocybin Rescheduling Initiative, among other leading partners in psychedelic research
Our team
Clara Burtenshaw
Investor
Biotech and life sciences investor with significant transactional, VC, IP and operational experience. Voted among the top 16 most influential women in psychedelics by Business Insider
- Board advisor to the International Therapeutic Psilocybin Rescheduling Initiative
- 5 years as GC at a PE-backed major retail group
- 5 years at Slaughter and May, focusing on M&A, IPOs and corporate finance
- Graduate from Oxford University, and NYU School of Law
Sean McLintock
Investor
Entrepreneur and longtime investor with deep wealth planning, trade finance and family office experience
- Previously at Andela, a high growth technology company backed by Google Ventures
- Founder of ThreeDots, a CBD beverage company in the UK
- Graduate of Stellenbosch University, Chicago Booth Business School, and Columbia University
Fergus Argyle
Investor
Experienced public and private company investor, across both credit and equity markets. Deep sector expertise in broad technology, med-tech, pharmaceuticals and biologics
- Career spanning roles at Blackrock to leading positions in boutique investment firms in London and Asia
- Graduate of Oxford University, and studied at the University of Damascus and Said Business School
Dr. Peter Crane
Chemical biology
Venture partner with healthcare investment and pharmaceutical expertise:
- Prior roles with corporate strategy and deep technology start-up accelerators
- DPhil in Chemical Biology from Oxford University and masters in chemistry (top of year) from Warwick University
Dr. Willem Hendrik Gispen
Neuropharmacology
Medical biologist and neuroscientist with distinguished academic positions including:
- Head of the Department of Molecular Neurobiology; Dean of the Faculty of Medicine; and Rector Magnificus of Utrecht University
- Director of the Rudolf Magnus Institute for Neuroscience
- President of the Federation of European Neuroscience Societies
- Editor in chief of the European Journal of Pharmacology
Isabel Fox
Advisory Board
Council member at Innovate UK and General Partner at Outsized Ventures
Prior to founding Outsized Ventures, Isabel was head of Venture Capital at White Cloud Capital here she focused on early stage investments in life sciences and healthcare
Lomax Ward
Advisory Board
Co-Founder and General Partner at Outsized Ventures fund focussing on human health
Previously a healthcare and life science investor at White Cloud and a corporate lawyer at Slaughter and May
Christina Sass
Advisory Board
Executive Coach with Talentism and the Co-Founder and Chair of Andela
Christina and her team raised over $181M in venture capital and grew to 2k+ employees with a $50M run rate in 6 years
Formerly at the MasterCard Foundation and the Clinton Global Initiative
Featured in
Media
Contact us
Sign up to our newsletter
© 2021 All Rights Reserved | Neo Kuma Ventures
71-75 Shelton Street, Covent Garden, London WC2H 9JQ
Neo Kuma Ventures LLP is an Appointed Representative of The Fund Incubator Limited which is authorised and regulated by the Financial Conduct Authority (FRN 208716)